Efficacy and Safety of Eptinezumab in Episodic Cluster Headache: A Randomized Clinical Trial.

ABSTRACT:

Importance

Cluster headache, characterized by bouts of excruciating pain attacks, detrimentally affects health and quality of life. Eptinezumab is an anticalcitonin gene-related peptide monoclonal antibody approved for migraine prevention.

Objective

To evaluate the efficacy and safety of eptinezumab in the preventive treatment of episodic cluster headache.

Design, setting, and participants

This double-blind, placebo-controlled, randomized (1:1) clinical trial (Eptinezumab in Participants With Episodic Cluster Headache [ALLEVIATE]) was conducted between December 2020 and October 2023. Results are from the initial 4-week randomized phase. The study took place at 64 sites across Europe, the US, and Japan. Included were adults (aged 18-75 years) with a history of episodic

SUBMITTER: Jensen RH 

PROVIDER: S-EPMC12090066 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature